Funding profile · Exosome therapeutics

Entelexo Biotherapeutics

A three-person preclinical company with one granted patent, one Regulation Crowdfunding offering on file and no Form D. The SEC record stops in July 2021.

$32,890Raised in the 2021 Regulation CF offering, reported by Wefunder
80Investors in that offering, about $411 each
$1.07MMaximum the offering was cleared to raise
0Form D filings on record with the SEC

Data as of September 24, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
Apr 2020 Incorporation in Delaware Not applicable Founders Milad Riazifar, Charles Cameron Taylor, Todd Schurr Form C
Winter 2021 Y Combinator, W21 batch Not disclosed Y Combinator Platform listing
By 2021 Pre-seed, listed as completed on the company roadmap Not disclosed Not named Company-stated
Jun 2021 to Apr 2022 Regulation CF offering of SAFEs through Wefunder Portal LLC $20,000 minimum, $1,070,000 maximum; $32,890 reported raised 80, per Wefunder Form C and platform
As stated in 2021 Total raised to that point More than $1M, plus $310K on the same terms Not named Company-stated
Never Regulation D offering None None No Form D

What the filings show

Entelexo Biotherapeutics Inc. · Form C · filed Jun 24, 2021

Security
Simple Agreement for Future Equity (SAFE), sold in $1 increments
Target
$50,000
Maximum
$1,070,000 · oversubscription accepted
Deadline
Apr 30, 2022
Intermediary
Wefunder Portal LLC, CRD 283503 · fee 3.75% of the offering amount
Co-issuer
Entelexo I, a series of Wefunder SPV, LLC, formed Jun 22, 2021
FY2020 books
Total assets $357,261 · cash $305,905 · revenue $0 · cost of goods sold $9,292 · taxes paid $23,575 · net income minus $70,818
Employees
3
Signatories
Milad Riazifar (CEO), Charles Cameron Taylor (CTO), Todd Schurr (COO)
Filing
SEC EDGAR, CIK 0001867546 · incorporated in Delaware Apr 22, 2020

Entelexo Biotherapeutics Inc. · Form C/A · filed Jul 2, 2021

Nature of amendment
“Lowered minimum fundraise target from $50K to $20K”
New target
$20,000
Maximum
Unchanged at $1,070,000
Deadline
Unchanged at Apr 30, 2022
Financials
Unchanged from the original filing
Filing
SEC EDGAR, file number 020-28286 · the company’s most recent filing of any kind

Reading the filings

  1. The round closed near the floor, not the ceiling.Wefunder reports $32,890 from 80 investors. Against the $1,070,000 maximum in the Form C, that is about 3.1 percent of what the offering was cleared to take. Average check: $32,890 divided by 80 is about $411.
  2. The floor moved before the money did.The original Form C set a $50,000 minimum on June 24, 2021. Eight days later the company filed an amendment whose stated purpose was to lower that minimum to $20,000, a cut of 60 percent. Reducing the target early is what an issuer does to make sure a thin offering still closes.
  3. The larger number the company quotes has no filing behind it.The Wefunder page claims more than $1 million raised to date plus $310,000 on the same terms. EDGAR shows no Form D for Entelexo Biotherapeutics, under that name or any other. That is not proof the money did not arrive: companies raising under Section 4(a)(2) rather than Regulation D file no Form D at all, and Y Combinator investments often sit in that category. It does mean no filing confirms the figure.
  4. The 2020 books were small and clean.At fiscal year end 2020 the company reported $357,261 in total assets, of which $305,905 was cash, against zero revenue, zero short-term debt, zero long-term debt and a net loss of $70,818. The prior year is all zeros because the company was incorporated in April 2020. Three employees. A $70,818 annual burn against $305,905 in cash is the arithmetic of a company running on founder time and grant-free savings, not one paying for animal studies.
  5. EDGAR has been silent for five years.The July 2, 2021 Form C/A is the last filing of any kind. The SEC’s own compliance guide states that “An issuer that sold securities in a Regulation Crowdfunding offering is required to provide an annual report on Form C-AR no later than 120 days after the end of its fiscal year,” and that an issuer ending that obligation files a Form C-TR. Neither form appears. The absence is a fact about the record, not a finding about the company.
  6. The asset on record is the patent, not the cap table.US 11,851,470 B2 was granted on December 26, 2023, assigned to Entelexo Biotherapeutics, Inc. of Irvine, with all three founders as inventors. That grant is two and a half years after the last securities filing and is the only public event tied to the company since.

Commercial signals

Signal Detail Source type
Regulatory No FDA clearance, approval or IND on the public record. The FDA stated in December 2019 that there are no approved exosome products, and none has been approved since. Public record
Clinical No study in ClinicalTrials.gov names the company as of Sep 24, 2026. Not found
Intellectual property One granted US patent, 11,851,470 B2. A second family, PCT/US2021/064186, drew an international search report in Mar 2022. Public record
Non-dilutive funding No NIH or NSF award found for the company. NSF hits under the name belong to other firms. Not found
Revenue $0 reported for fiscal 2020, the only year on file. No later financials disclosed. Public record
Product Company says lead candidates are selected and evaluated in human cell immunoassays, with pre-IND preparation as the next milestone. No data published. Company-stated
Web presence Site copy unchanged, carrying a 2022 copyright line; a Nov 27, 2025 archive capture matches the live page. Public record

What to watch

  • A Form C-AR or a Form C-TR. Either would show whether the issuer is still reporting.
  • A first Form D, which would mark a priced or institutional round.
  • An IND or a trial registration, the two events that would move this from platform to program.
  • Continuations or national phase entries out of PCT/US2021/064186.

The Entelexo Biotherapeutics story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Forever Labs: Also in Therapeutics. An Ann Arbor company that cryopreserves an adult’s own stem cells against the possibility of a future therapy
  • SFA Therapeutics: Also in Therapeutics. A Temple University spinout turning short chain fatty acids from the human gut into oral pills
  • Eris Biotech: Also in Therapeutics. A two-founder Utah company building an oral small molecule that stops tumors from releasing the vesicles they use to switch off the immune system
  • Asher Bio: Also in Therapeutics. A South San Francisco company rebuilding interleukin-2 so it reaches only the killer T cells that attack tumors

Sources

  1. Public recordForm C, Entelexo Biotherapeutics Inc., CIK 0001867546SEC EDGAR · Jun 24, 2021
  2. Public recordForm C/A, amendment lowering the minimum targetSEC EDGAR · Jul 2, 2021
  3. Public recordRegulation Crowdfunding: A Small Entity Compliance Guide for IssuersSEC · 2016
  4. Public recordRegulation Crowdfunding overview pageSEC · reviewed Apr 24, 2025
  5. Public recordUS Patent 11,851,470 B2, assignee and inventor listingUSPTO via Justia · granted Dec 26, 2023
  6. Public recordPublic Safety Notification on Exosome ProductsFDA · Dec 6, 2019
  7. Public recordRegistry query for EntelexoClinicalTrials.gov · Sep 24, 2026
  8. CompanyEntelexo (YC W21) offering page, raise totals and quick factsWefunder · accessed Sep 24, 2026
  9. CompanyEntelexo Biotherapeutics website and roadmapentelexo.com · accessed Sep 24, 2026
  10. CompanyEntelexo Biotherapeutics portfolio page, founders and team sizeFounders, Inc. · accessed Sep 23, 2026
  11. IndependentRegulation of exosomes as biologic medicinesClinical and Translational Science · Aug 2024

Compiled from SEC, USPTO, FDA and ClinicalTrials.gov public records and published reports as of September 24, 2026. Form C notices report offerings under Regulation Crowdfunding; amounts reflect the filing date and the portal’s reported totals. Healthcare Venture Capital Fund holds no position in Entelexo Biotherapeutics. This page is not an offer to sell or a recommendation to buy any security.